Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals
Livia Maria Gonçalves Rossi1 & Paula Rahal1 Show affiliations
- São Paulo State University, Brazil
American Journal of Infectious Diseases, Volume 10, Issue 4, pp. 179–183 · doi.org/10.3844/ajidsp.2014.179.183
Abstract
Hepatitis C Virus (HCV) infects millions of people and represents an important public health problem in different regions of the world. Drug resistance is a major challenge for HCV-infection related control. Importantly, the arrival of a plethora of novel, more powerful drugs has revolutionized the field of HCV treatment. Here, we discuss the relevance of identification of HCV resistant mutants from a clinical standpoint. The advantage and limitations of molecular testing in clinical setting is presented.
Licence and reuse
Open access. This article is licensed under a Creative Commons Attribution 3.0 Licence (CC BY 3.0), as printed on the article, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original authors and the source. No permission is needed.
How to reuse this articleResponses (0)
About this article
Gonçalves Rossi, L. M. & Rahal, P. (2014). Detection of Hepatitis C Virus Resistant Mutants in the era of Direct Acting Antivirals. American Journal of Infectious Diseases, 10(4), 179–183. https://doi.org/10.3844/ajidsp.2014.179.183
- Licence
- CC BY 3.0
- Issue
- Volume 10, Issue 4
- Policies
- Editorial independenceUse of generative AIData availabilityAppeals and complaints
- Version
- Version of record